Samarium (153Sm) lexidronam

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Samarium (153Sm) lexidronam
153Sm-lexidronam structure.svg
Clinical data
License data
  • US: D (Evidence of risk)
Routes of
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass695.93 g/mol
3D model (JSmol)

Samarium (153Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.[1][2]

It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope 153Sm, with a half-life of 46.3 hours, decays by emitting beta particles (electrons), which kill the nearby cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma.

Side effects[edit]

Side effects[3] include the following:

  • Black, tarry stools
  • Blood in urine/stool
  • Cough, hoarseness
  • Fever/chills
  • Lower back/side pain
  • Painful or difficult urination
  • Pinpoint red spots on skin
  • Irregular heartbeat
  • Nausea, vomiting

Supply and administration[edit]

Samarium lexidronam is supplied as a frozen solution for intravenous use with an activity of 50±5 mCi/mL[4] and a maximum beta energy of 0.808 MeV.[5] Due to the short half-life of the radioisotope, the drug expires 56 hours after the noted calibration time.[4]


  1. ^ Anderson P (August 2006). "Samarium for osteoblastic bone metastases and osteosarcoma". Expert Opinion on Pharmacotherapy. 7 (11): 1475–86. doi:10.1517/14656566.7.11.1475. PMID 16859431.
  2. ^ Finlay IG, Mason MD, Shelley M (June 2005). "Radioisotopes for the palliation of metastatic bone cancer: a systematic review". The Lancet. Oncology. 6 (6): 392–400. doi:10.1016/S1470-2045(05)70206-0. PMID 15925817.
  3. ^ "Quadramet Side Effects in Detail".
  4. ^ a b FDA Professional Drug Information on Quadramet. 2009.
  5. ^ Bé M, Coursol N, Duchemin B, Lagoutine F, Legrand J. "Table of Radionuclides" (PDF). Henry Becquerel National Laboratory. Retrieved 22 April 2020.